Supported by Grants from Carl Zeiss Meditec, Inc. (Dublin, CA), the Salah Foundation, the National Eye Institute Center Core Grant (P30EY014801), and Research to Prevent Blindness (unrestricted Grant) to the Department of Ophthalmology, University of Miami Miller School of Medicine. The funding organization had no role in the design or conduct of this research.
Disclosure: X. Jiang, None; M. Shen, None; L. Wang, None; L. de Sisternes, Carl Zeiss Meditec, Inc. (E); M.K. Durbin, Carl Zeiss Meditec, Inc. (E); W. Feuer, None; P.J. Rosenfeld, Apellis (C, I), Biogen (C), Boehringer-Ingelheim (C), Carl Zeiss Meditec (F, C), Chengdu Kanghong Biotech (C), EyePoint (C), Ocunexus Therapeutics (C), Ocudyne (C, I), Regeneron Pharmaceuticals (C), Stealth BioTherapeutics (F), Unity Biotechnology (C), Valitor Verana Health (I); G. Gregori, Carl Zeiss Meditec, Inc. (F, P)